37 results
6-K
EX-99.1
NTBL
Notable Labs Ltd
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
, providing a novel and differentiated approach with potential applications in various chronic inflammatory indications.
Prof. Dror Harats delivered
6-K
EX-99.1
NTBL
Notable Labs Ltd
23 Mar 22
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
7:33am
for prevalent and chronic inflammatory disorders, expected to enter the clinic in 2H 2022
KOL event in NYC to discuss ofra-vec in ovarian cancer planned … studies have been successfully completed for VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders
6-K
EX-99.1
NTBL
Notable Labs Ltd
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
monocytes for prevalent and chronic inflammatory disorders, expected to enter the clinic in the second half of 2022
TEL AVIV, Israel and NEW YORK … .
IND-enabling toxicology studies are underway for VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders
6-K
qch66vr8
16 Aug 21
Current report (foreign)
7:00am
6-K
var4iei
11 May 21
Current report (foreign)
7:00am
6-K
EX-99.3
q4qo vqv829u8
15 Jan 21
Ordinary Share Purchase Agreement
7:01am
424B5
hcr78d9hys oc
15 Jan 21
Prospectus supplement for primary offering
7:00am
424B3
dlst80 9ifba
16 Nov 20
Prospectus supplement
7:15am
6-K
ms6hizkjrxy8iq
16 Nov 20
Current report (foreign)
7:00am
424B3
6crljk 6ltjggiapzn
26 Aug 20
Prospectus supplement
5:21pm
6-K
khmpmd81asdtfd7q4ja8
13 Aug 20
Current report (foreign)
7:00am
F-1
82elv cji
1 Jun 20
Registration statement (foreign)
12:18pm
6-K
ceozx 6d6m
14 May 20
Current report (foreign)
7:25am
424B5
de3 oecne
12 May 20
Prospectus supplement for primary offering
12:02pm
424B5
rr302fxlmw3vc
11 May 20
Prospectus supplement for primary offering
9:23am
6-K
1iunbbhomdgbjxvug
14 Nov 19
Current report (foreign)
7:01am